CD4 News and Research

RSS

Some HIV-positive Ugandans' not receiving antiretrovirals

Some HIV-positive people in Uganda "cannot be put on the national antiretroviral [ARV] programme because it is already saturated and funds for new patients are not available," the Independent reports. According to the newspaper, roughly 360,000 HIV-positive Ugandans are eligible for antiretroviral treatment because their CD4 counts are below the WHO's threshold of 350; however, about half of them currently do not have access to ARVs.

20 Aug 2009

Retrovirox receives another NIH grant for novel inhibitors of HIV entry

RetroVirox, Inc., a biotechnology company specializing in the development of novel antivirals, announced today that it has received a grant award of $296,875 from the National Institute of Allergy and Infectious Disease (NIAID), of the National Institutes of Health (NIH). This is the second award to RetroVirox from the NIH in less than six months. In March 2009 the company received its first grant to develop novel inhibitors of HIV entry.

12 Aug 2009

New research helps explain why treated genital herpes sores boost risk of HIV infection

New research helps explain why infection with herpes simplex virus-2 (HSV-2), which causes genital herpes, increases the risk for HIV infection even after successful treatment heals the genital skin sores and breaks that often result from HSV-2.

3 Aug 2009

Immune responses to flu vaccine are diminished in lupus patients

Patients with the autoimmune disease systemic lupus erythematosus (SLE) have an increased risk of infection, due to both disturbances in their immune responses and treatment with immunosuppressive drugs.

30 Jul 2009

Prevention, vaccines addressed at IAS conference

During the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention meeting in Cape Town, South Africa, scientists "renewed the call for more immediate and urgent effort to be directed towards HIV prevention amid the dominance of treatment interventions and the world-wide search for a quick fix vaccine, which many agree, is years away," Health-e/allAfrica.com reports (Thom, 7/22).

22 Jul 2009

Discovery of genetic trigger for disease-fighting antibodies

A research team led by the La Jolla Institute for Allergy & Immunology has identified the specific gene which triggers the body to produce disease-fighting antibodies -- a seminal finding that clarifies the exact molecular steps taken by the body to mount an antibody defense against viruses and other pathogens.

17 Jul 2009

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough Corporation has announced that it has extended to stage two an ongoing Phase II clinical study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. In this study, vicriviroc is being evaluated in a novel nucleoside-sparing regimen that is designed to provide additional options for treatment-naive patients in a once daily regimen, while preserving other drug classes for subsequent lines of treatment.

15 Jul 2009

Peptic ulcer bacterium alters the body's defence system

Helicobacter pylori survives in the body by manipulating important immune system cells. This is shown in a thesis from the Sahlgrenska Academy, University of Gothenburg, Sweden. The discovery may lead to new treatments against the common peptic ulcer bacterium.

30 Jun 2009

Transplant drug Rapamycin stimulates immune memory

Rapamycin, a drug given to transplant recipients to suppress their immune systems, has a paradoxical effect on cells responsible for immune memory, scientists at the Emory Vaccine Center have discovered.

22 Jun 2009

Antiretroviral therapy earlier yields better clinical outcomes

A clinical trial has demonstrated that HIV-infected adults in a resource-limited setting are more likely to survive if they start antiretroviral therapy (ART) before their immune systems are severely compromised.

9 Jun 2009

Drug derived from the hydrangea root shows promise for autoimmune disorders

A drug derived from the hydrangea root, used for centuries in traditional Chinese medicine, shows promise in treating autoimmune disorders, report researchers from the Program in Cellular and Molecular Medicine and the Immune Disease Institute at Children's Hospital Boston (PCMM/IDI), along with the Harvard School of Dental Medicine.

4 Jun 2009

Discovery of biochemical signals that help immune cells remember how to fight infection

Immunology researchers at UT Southwestern Medical Center have discovered how two biochemical signals play unique roles in promoting the development of a group of immune cells employed as tactical assassins.

28 May 2009

Researchers develop questions to determine risk of HIV/AIDS drug resistance

Researchers from the Makerere University hospital in Uganda, the U.S. and Belgium have developed a formula, based on a set of questions, for determining HIV-positive people's risk of treatment failure and drug resistance, according to a study recently published in the Journal of the International AIDS Society, the New York Times reports.

19 May 2009

Research may lead to improved TB vaccines

A team of Vanderbilt University Medical Center investigators has cracked one of clinical medicine's enduring mysteries - what happened to the tuberculosis vaccine. The once-effective vaccine no longer prevents the bacterial lung infection that kills more than 1.7 million people worldwide each year.

19 May 2009

Chronic infection clearly linked to key immunity protein

The reason deadly infections like human immunodeficiency virus (HIV) and hepatitis C never go away is because these viruses disarm the body's defense system.

15 May 2009

Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says

The drug acyclovir, which suppresses herpes simplex virus-2, does not reduce the risk of HIV transmission when taken by HIV-positive people who also have herpes, according to a study conducted by researchers at the University of Washington, United Press International reports.

14 May 2009

IRIN/Plus News examines HIV/AIDS services in Zimbabwe following economic crisis

IRIN/Plus News on Monday examined services for people living with HIV/AIDS in Zimbabwe following an economic crisis in the country.

12 May 2009

Study reveals current multi-component vaccines may need reworking

Current strategies for designing vaccines against HIV and cancers, for instance, may enable some components in multi-component vaccines to cancel the effect of others on the immune system, eliminating their ability to provide protection, according to an article to be published shortly in the Proceedings of the National Academy of Sciences (PNAS).

7 May 2009

Early initiation of antiretroviral therapy improves HIV survival rates, study says

The New York Times on Thursday examined a study that found asymptomatic HIV-positive people who delayed antiretroviral treatment until their disease reached an advanced stage faced higher mortality rates than those who initiated treatment earlier.

30 Apr 2009

If started early, HIV treatment reduces death rates toward background levels in African countries

Mortality rates of people starting HIV treatment in four African countries approach those of the general population over time, provided that treatment is started before the immune system has been severely damaged, according to research published this week in the open-access journal PLoS Medicine.

30 Apr 2009